Iohimbine "Der Spiegel" ® (Yohimbin "Spiegel" ®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceYohimbine hydrochlorideYohimbine hydrochloride
Dosage form: & nbsppills
Composition:

1 tablet contains:

active substance: Iohimbine hydrochloride 5 mg;

auxiliary substances: corn starch 6.0 mg, gum arabic 6.0 mg, lactose monohydrate 110.0 mg, sucrose 116.0 mg, stearic acid 3.0 mg, talc 4.0 mg.

Description:

White, round, flat tablets with bevelled edges.

Pharmacotherapeutic group:Erectile dysfunction medication is an alpha-blocker
ATX: & nbsp

G.04.B.E.04   Yohimbine

Pharmacodynamics:

Alpha2-adrenoblocker, mainly affects presynaptic central and peripheral alpha2-adrenoceptors. Improves blood circulation of the pelvic organs. Activates adrenergic neurons of the central nervous system (which can be accompanied by increased blood pressure), motor activity and reactivity.

Increases libido and potency. Has antidiuretic effect, causes an increase in heart rate and a decrease in blood pressure (due to blockade of peripheral alpha2adrenoreceptors).

Pharmacokinetics:

Quickly and completely absorbed from the gastrointestinal tract. The maximum concentration is achieved after 1.3 hours. 10 minutes after ingestion, it penetrates the blood-brain barrier, about 17% is detected in the brain tissues within 6 hours. Metabolised in the liver. The elimination half-life is 0.6 hours.

Indications:

Psychogenic impotence, functional impotence (accompanied by erectile dysfunction), atony of the bladder, menopause.

Contraindications:

Hypersensitivity to the drug, hepatic and / or renal failure, hypertension or hypotension, coronary heart disease, simultaneous reception of adrenostimulators.

Carefully:

Stomach ulcer and duodenal ulcer, mental illness.

Dosing and Administration:

Inside, 1-2 tablets (5-10 mg) 1-3 times a day, while eating, without chewing and drinking a glass of water.

The course of treatment is 3-10 weeks. If necessary, the course can be repeated no earlier than 10 weeks.

Side effects:

Dizziness, headache, anxiety, migraines, hand tremors, vomiting, diarrhea, gastralgia, decreased or increased blood pressure,orthostatic hypotension, tachycardia.

Overdose:

Symptoms: general weakness, generalized paresthesia, memory impairment, and headache, dizziness, tremor, tachycardia, increased blood pressure, a sense of fear, hallucinations, nausea, vomiting, mydriasis, saliva and lacrimation, increased sweating, increased norepinephrine in the blood plasma.

Treatment: antidote - clonidine; prescribe inside at an initial dose of 0.1-0.2 mg, then again with hour intervals at a dose of 0.1 mg.

Symptomatic treatment: antihypertensive drugs; To eliminate feelings of fear or hallucinations, prescribe benzodiazepines (do not prescribe neuroleptics phenothiazine series).

Interaction:

With simultaneous admission with clonidine - the weakening effect of both drugs.

Possible a decrease in the effectiveness of antihypertensive drugs, alprazolam.

Strengthens the action of antidepressants.

Clomipramine increases the concentration of yohimbine hydrochloride in blood plasma.

Special instructions:

It is not recommended to combine with antidepressants and other timoleptic drugs.

Effect on the ability to drive transp. cf. and fur:

During the treatment period it is necessary to refrain from driving motor vehicles and practicing potentially dangerous activities that require an increased concentration of attention, acuity and speed of psychomotor reactions.

Form release / dosage:Tablets, 5 mg.
Packaging:

For 20 tablets in a bottle of colorless glass type III, sealed with a plastic lid with the control of the first autopsy.

1 bottle with instructions for use in a cardboard box.

Storage conditions:

In a dry place, at a temperature of no higher than 25 ° C.

Keep out of the reach of children.
Shelf life:

5 years.

Do not use after the expiry date printed on the package.

Terms of leave from pharmacies:On prescription
Registration number:П N016235 / 01
Date of registration:07.04.2010
Expiration Date:Unlimited
The owner of the registration certificate:Pharmaselect International Betaigigungs, GmbHPharmaselect International Betaigigungs, GmbH Germany
Manufacturer: & nbsp
Representation: & nbspPharmaselect International Betaigigungs, GmbHPharmaselect International Betaigigungs, GmbHAustria
Information update date: & nbsp27.11.2017
Illustrated instructions
    Instructions
    Up